ArticleBMJ open respiratory research2024
Use of metered dose inhalers for bronchodilator responsiveness testing: laboratory practices in Australia and opportunities for carbon footprint reduction.
Article in BMJ open respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetered dose inhalers (MDIs) are important devices for delivering inhaled medications; however, they have an outsized carbon footprint due to their propellant gas. Many short-acting beta-agonist inhalers contain HFA-134a which has a global warming potential >1000 fold higher than carbon dioxide. We aimed to determine the practices around MDI use and disposal within Australia's major lung function testing laboratories and identify the actions that most influence the carbon footprint of bronchodilator responsiveness (BDR) testing.
methodsAustralia's 45 accredited lung function laboratories were invited to participate in an online survey asking about their volume of BDR testing, as well as practices around MDI use such as the number of actuations per BDR test, reuse of MDIs between patients and disposal method. We calculated MDI-associated carbon dioxide equivalent (CO2e) emissions by combining previously published estimates.
results39 laboratories completed the survey. Most laboratories used 4 actuations of salbutamol per BDR test for both adults (27/34, 79.4%) and children (17/20, 85%), but this ranged from 2 to 12. Only three (7.7%) laboratories did not routinely reuse MDIs between patients; however, they all sent their used MDIs for high-temperature incineration. Based on different combinations of observed MDI practices in Australia, we identified a potential sixfold difference in CO2e per 100 BDR tests, from as low as 23.3 kg CO2e up to 166 kg CO2e.
conclusionsWe identified three key practices to reduce the carbon footprint of BDR testing: disposing of MDIs via high-temperature incineration, reducing the number of actuations per BDR test and reusing MDIs between patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.